ISRCTN43187439已完成不适用
A randomised, single centre, phase IV crossover study to assess the acceptability of once daily Zindaclin® used for one week compared to three other marketed topical antibiotics in patients with mild to moderate acne
ProStrakan Pharmaceuticals (UK)0 个研究点目标入组 65 人开始时间: 2005年10月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Male and female patients aged between 16 and 40 years with mild to moderate acne graded between 1.0 and 7.0 on the Leeds Revised Acne Grading System, 1998.
排除标准
- •1. Patients with acne conglobata, acne fulminans, sandpaper acne, submarine comedonal acne or secondary acne were excluded
- •2. The use of topical or systemic antibiotics or topical antimicrobials within the previous week was disallowed
研究者
相似试验
进行中（未招募）
不适用
Study to investigate the effect of Gaviscon® Double Action, Gaviscon® Advance and Placebo Liquid Vs no treatment on the acid pocket.EUCTR2012-000678-44-GBReckitt Benckiser Healthcare (UK) Ltd
已完成
不适用
My Health Tags - To improve taking tablets for heart failureHeart failureSpecialty: Cardiovascular disease, Primary sub-specialty: Heart failureUKCRC code/ Disease: Cardiovascular/ Hypertensive diseasesCirculatory SystemISRCTN58513123niversity Hospitals Bristol NHS Foundation Trust30
进行中（未招募）
1 期
PRECYCLE: Multicenter, randomized phase IV intergroup trial to evaluate the impact of e Health-based patient reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with Palbociclib and an aromatase inhibitor- or Palbociclib and Fulvestrant - PreCycleEUCTR2016-004191-22-DEPalleos healthcare GmbH960
进行中（未招募）
不适用
An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced antigen content diphtheria-tetanus toxoids andacellular pertussis vaccine (Boostrix), when administered in young adults, 10 years after previous booster vaccination in study 263855/004 (dTpa-004). - DTPA (BOOSTRIX): 040 EXT Y10EUCTR2007-003248-31-FIGSK Biologicals
已完成
不适用
A phase I, open-label, randomized, 4-way crossover study in subjects with chronic Hepatitis B virus infection to assess pharmacokinetics (fasted/fed), safety, tolerability and pharmacodynamics of single oral doses of Farnesoid X receptor agonist EYP001a.Hepatitis Bviral infection of the liver10019654NL-OMON45541ENYO Pharma SA14